SITE013-0257

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-12-22

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-21 (study day 14); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 19); relationship: not assessed

severe serious assessed

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 23); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 55); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 64); relationship: Y

Data queries

No data queries.